TY - JOUR
T1 - Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer
T2 - a study of the Chronic Malignancies Working Party of the EBMT
AU - Nabergoj, Mitja
AU - Mauff, Katya
AU - Beelen, Dietrich
AU - Ganser, Arnold
AU - Kröger, Nicolaus
AU - Stölzel, Friedrich
AU - Finke, Jürgen
AU - Passweg, Jakob
AU - Cornelissen, Jan
AU - Schub, Natalie
AU - Veelken, Joan Hendrik
AU - Beguin, Yves
AU - Wilson, Keith
AU - Zuckerman, Tsila
AU - Hunault-Berger, Mathilde
AU - Lioure, Bruno
AU - Porras, Rocio Parody
AU - Turlure, Pascal
AU - Kerre, Tessa
AU - Koster, Linda
AU - Hayden, Patrick J.
AU - Onida, Francesco
AU - Scheid, Christof
AU - Chalandon, Yves
AU - Robin, Marie
AU - Yakoub-Agha, Ibrahim
N1 - Funding Information:
Funding for this study was indirectly provided by support of the CMWP of the EBMT.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/7
Y1 - 2022/7
N2 - We performed a registry study on therapy-related myeloid neoplasm (t-MN), both therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) following treatment for breast cancer who underwent a first allogeneic hematopoietic cell transplant (allo-HCT). Of 252 identified female patients (median age 57 years), 77% were transplanted for t-AML and 23% for t-MDS, with a median time from breast cancer diagnosis to the diagnosis of tMN and subsequent allo-HCT of 3.7 and 4.6 years, respectively. At transplant, 191 patients were in remission for breast cancer, while 4 were not (57 missing). T-MN was in a complete remission at the time of transplant in 67% of patients. 2-year overall survival, relapse free-survival, relapse incidence and non-relapse mortality were 50%, 45%, 33%, and 22%, respectively. Multivariable analysis revealed that if the t-MN was not in CR pre-transplant, this was associated with lower OS, RFS, and a higher relapse incidence. Seventeen cases of breast cancer recurrence were recorded after a median of 2.4 years post-transplant, and relapse of primary breast cancer accounted for 7% of deaths. This study indicates that allo-HCT for t-MN following treatment for breast cancer shows encouraging transplant outcomes. The incidence of breast cancer relapse post-transplant remains a cause for concern.
AB - We performed a registry study on therapy-related myeloid neoplasm (t-MN), both therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) following treatment for breast cancer who underwent a first allogeneic hematopoietic cell transplant (allo-HCT). Of 252 identified female patients (median age 57 years), 77% were transplanted for t-AML and 23% for t-MDS, with a median time from breast cancer diagnosis to the diagnosis of tMN and subsequent allo-HCT of 3.7 and 4.6 years, respectively. At transplant, 191 patients were in remission for breast cancer, while 4 were not (57 missing). T-MN was in a complete remission at the time of transplant in 67% of patients. 2-year overall survival, relapse free-survival, relapse incidence and non-relapse mortality were 50%, 45%, 33%, and 22%, respectively. Multivariable analysis revealed that if the t-MN was not in CR pre-transplant, this was associated with lower OS, RFS, and a higher relapse incidence. Seventeen cases of breast cancer recurrence were recorded after a median of 2.4 years post-transplant, and relapse of primary breast cancer accounted for 7% of deaths. This study indicates that allo-HCT for t-MN following treatment for breast cancer shows encouraging transplant outcomes. The incidence of breast cancer relapse post-transplant remains a cause for concern.
UR - http://www.scopus.com/inward/record.url?scp=85128717269&partnerID=8YFLogxK
U2 - 10.1038/s41409-022-01686-7
DO - 10.1038/s41409-022-01686-7
M3 - Article
C2 - 35459878
AN - SCOPUS:85128717269
SN - 0268-3369
VL - 57
SP - 1072
EP - 1078
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 7
ER -
